TY - JOUR
T1 - Advances in emerging drugs for osteosarcoma
AU - Hattinger, Claudia Maria
AU - Fanelli, Marilù
AU - Tavanti, Elisa
AU - Vella, Serena
AU - Ferrari, Stefano
AU - Picci, Piero
AU - Serra, Massimo
PY - 2015/7/3
Y1 - 2015/7/3
N2 - Introduction: Osteosarcoma (OS), the most common primary malignant bone tumor, is currently treated with pre- and postoperative chemotherapy in association with the surgical removal of the tumor. Conventional treatments allow to cure about 60 - 65% of patients with primary tumors and only 20 - 25% of patients with recurrent disease. New treatment approaches and drugs are therefore highly warranted to improve prognosis.Areas covered: This review focuses on the therapeutic approaches that are under development or clinical evaluation in OS. Information was obtained from different and continuously updated data bases, as well as from literature searches, in which particular relevance was given to reports and reviews on new targeted therapies under clinical investigation in high-grade OS.Expert opinion: OS is a heterogeneous tumor, with a great variability in treatment response between patients. It is therefore unlikely that a single therapeutic tool will be uniformly successful for all OS patients. This claims for the validation of new treatment approaches together with biologic/(pharmaco)genetic markers, which may select the most appropriate subgroup of patients for each treatment approach. Since some promising novel agents and treatment strategies are currently tested in Phase I/II/III clinical trials, we may hope that new therapies with superior efficacy and safety profiles will be identified in the next few years.
AB - Introduction: Osteosarcoma (OS), the most common primary malignant bone tumor, is currently treated with pre- and postoperative chemotherapy in association with the surgical removal of the tumor. Conventional treatments allow to cure about 60 - 65% of patients with primary tumors and only 20 - 25% of patients with recurrent disease. New treatment approaches and drugs are therefore highly warranted to improve prognosis.Areas covered: This review focuses on the therapeutic approaches that are under development or clinical evaluation in OS. Information was obtained from different and continuously updated data bases, as well as from literature searches, in which particular relevance was given to reports and reviews on new targeted therapies under clinical investigation in high-grade OS.Expert opinion: OS is a heterogeneous tumor, with a great variability in treatment response between patients. It is therefore unlikely that a single therapeutic tool will be uniformly successful for all OS patients. This claims for the validation of new treatment approaches together with biologic/(pharmaco)genetic markers, which may select the most appropriate subgroup of patients for each treatment approach. Since some promising novel agents and treatment strategies are currently tested in Phase I/II/III clinical trials, we may hope that new therapies with superior efficacy and safety profiles will be identified in the next few years.
KW - drug resistance
KW - osteosarcoma
KW - pharmacogenetics
KW - pharmacogenomics
KW - tailored therapy
KW - targeted drugs
UR - http://www.scopus.com/inward/record.url?scp=84940390988&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84940390988&partnerID=8YFLogxK
U2 - 10.1517/14728214.2015.1051965
DO - 10.1517/14728214.2015.1051965
M3 - Article
C2 - 26021401
AN - SCOPUS:84940390988
VL - 20
SP - 495
EP - 514
JO - Expert Opinion on Emerging Drugs
JF - Expert Opinion on Emerging Drugs
SN - 1472-8214
IS - 3
ER -